Last reviewed · How we verify

Standard of Care FIX Replacement therapy

Pfizer · Phase 3 active Small molecule

Fix replacement therapy involves replacing the deficient or missing fix protein in the body.

Fix replacement therapy involves replacing the deficient or missing fix protein in the body. Used for Hemophilia A, Hemophilia B.

At a glance

Generic nameStandard of Care FIX Replacement therapy
SponsorPfizer
Drug classFix replacement therapy
TargetFix protein
ModalitySmall molecule
Therapeutic areaHemophilia
PhasePhase 3

Mechanism of action

This is typically done through injections or infusions to help restore normal fix levels and alleviate symptoms associated with fix deficiency.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: